Bizarre Patents
A gun that fires a missile, powered by gas "discharged by the operator of the toy."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6841534 | Protein Z-dependent protease inhibitor The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSP... | 01/11/2005 |
| 6809083 | Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nuc... | 10/26/2004 |
| 6747149 | Glucamine salts for treating hepatitis virus infections N-Substituted glucamine compounds of formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections the compounds of formular I may be used alone, or in combinatioin with another antiviral agent ... | 06/08/2004 |
| 6696059 | Combination drug therapy for glycolipid storage diseases A combination drug therapy is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of both a N-alkyl deriv... | 02/24/2004 |
| 6610703 | Method for treatment of glycolipid storage diseases A novel method is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of a long-chain N-alkyl derivative ... | 08/26/2003 |
| 6586250 | Method of PCR-based gene targeting An improved method of gene targeting, referred to as PCR-based gene targeting is disclosed, which generates cell lines or mice in which at least one allele of a specific gene is disrupted by double homologous recombination of a PCR-derived targeting vecto... | 07/01/2003 |
| 6528637 | Fatty acid synthase mRNA binding protein Disclosed is a 178 kDa glucose-inducible human fatty acid synthase (FAS) mRNA binding protein which has been purified to homogeneity and its binding element characterized. This large phosphoprotein binds to a novel repetitive element in the 3' untranslate... | 03/04/2003 |
| 6495570 | Combination drug therapy for glycolipid storage diseases A novel combination drug therapy is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of both a N-alkyl... | 12/17/2002 |
| 6469138 | Thrombospondin receptor binding peptides Novel short peptides are described that bind to the thrombospondin 1 receptor, which preferably have five amino acid residues which share the tetrapeptide Arg-Val-Ala-Val and have the following sequences: Ile-Arg-Val-Ala-Val [SEQ ID NO:13] and Val-Arg-Val-Ala-... | 10/22/2002 |
| 6403318 | Fatty acid synthase mRNA binding protein Disclosed is a 178 kDa glucose-inducible human fatty acid synthase (FAS) mRNA binding protein which has been purified to homogeneity and its binding element characterized. This large phosphoprotein binds to a novel repetitive element in the 3' untranslate... | 06/11/2002 |
| 6369031 | Protein Z-dependent protease inhibitor The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequen... | 04/09/2002 |
| 6291427 | Anticoagulant combination of LACI and sulfated polysaccharides There is disclosed herein a combination of lipoprotein-associated coagulation inhibition (LACI) and sulfated polysaccharides, e.g. heparin, which exerts a synergistic anticoagulant action in whole plasma.... | 09/18/2001 |
| 6291657 | Deoxygalactonojirimycin derivatives Novel N-alkyl derivatives of deoxygalactonojirimycin are provided in which said alkyl contains from 3-6 carbon atoms. These novel compounds are useful for selectively inhibiting glycolipid synthesis.... | 09/18/2001 |
| 6274703 | Method of cell surface activation and inhibition Disclosed are a peptide and its use in a method of screening test compounds as potential inhibitors of matrix metalloproteinases. The peptide consists of residues Trp 574 to Asp 656 in the TIMP-2 binding site of the C-terminal domain of gelatinase-A as sh... | 08/14/2001 |
| 6271367 | Protein Z-dependent protease inhibitor The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequen... | 08/07/2001 |
| 6268220 | Diagnostic method for atherosclerosis A diagnostic method and screening test for atherosclerosis and analogous diseases involving activated phagocytes and/or inflammation is provided which comprises determining the presence of 3-chlorotyrosine in a test sample of a body fluid or tissue at a l... | 07/31/2001 |
| 6265378 | Protein Z-dependent protease inhibitor The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequen... | 07/24/2001 |
| 6245741 | Protein Z-dependent protease inhibitor The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequen... | 06/12/2001 |
| 6204043 | Human macrophage metalloproteinase A novel 54 kDa human macrophage metalloelastase (HME) having elastolytic activity and the cDNA which encodes for this enzyme are disclosed.... | 03/20/2001 |
| 6194189 | Catalytically-active gelatinase mutant A truncated mutant of the 92 kDa gelatinase is disclosed which is catalytically active comparable to the full-length enzyme but, unlike the full-length enzyme, is essentially inactive against insoluble elastin. The truncated mutant preferably comprises re... | 02/27/2001 |
| 6184021 | Catalytically-active gelatinase mutant A truncated mutant of the 92 kDa gelatinase is disclosed which is catalytically active comparable to the full-length enzyme but, unlike the full-length enzyme, is essentially inactive against insoluble elastin. The truncated mutant preferably comprises re... | 02/06/2001 |
| 6150152 | Human macrophage metalloelastase A novel 54 kDa human macrophage metalloelastase (HME) having elastolytic activity and the cDNA which encodes for this enzyme are disclosed.... | 11/21/2000 |
| 6136040 | Animal model with disrupted FGF-9 gene A unique animal model is disclosed which is useful for studying the role of FGF-9 activity in cardiovascular diseases. To provide this animal model, the FGF-9 gene is disrupted in mice, that is, null mutation in the mouse FGF-9 gene is engineered. This kn... | 10/24/2000 |
| 6133039 | In vivo method for determination of oxidative stress A non-invasive method for the determination of oxidative stress in a patient by urinalysis is disclosed. The method comprises quantifying the level of o,o'-dityrosine in a sample of the urine of said patient and comparing with the corresponding level of s... | 10/17/2000 |
| 6121417 | Inhibitors of retroviral protease Novel inhibitors of retroviral protease, e.g., HIV protease, are provided which are peptides having from about 4 to about 8 amino acid residues and which are substrates for said protease derived from known cleavage sites and modified to contain an interna... | 09/19/2000 |
| 6111080 | Monoclonal antibodies A monoclonal antibody which specifically reconizes a receptor that binds to proteins that contain the amino acid sequence Arg-Gly-Asp which on binding said proteins causes the cells to become substantially more phagocytic.... | 08/29/2000 |
| 6096556 | Method for the determination of oxidative stress A noninvasive method for the determination of oxidative stress in a patient is disclosed. The method comprises quantifying the levels or relative distribution of a pair of compounds, o,o'-dityrosine and o-tyrosine, in a sample of the patient's urine and c... | 08/01/2000 |
| 6083914 | Antithrombotic peptides Novel short peptides are disclosed which are selected from the group consisting of TAVTQTYGGNSNGEP and fragments thereof containing the minimal sequence TATQTY. These peptides are antithrombotic agents and mediate divalent cation-independent adhesion of p... | 07/04/2000 |
| 6069235 | Method for carbohydrate engineering of glycoproteins A method is disclosed for modifying the carbohydrate moiety on glycoproteins to facilitate the structural and functional analysis of said glycoproteins such as by NMR spectroscopic analysis and crystallography which comprises treating glycoprotein-secreti... | 05/30/2000 |
| 6048989 | Furyl containing fatty acids, glycosyl phosphatidylinositol (GPI) analogues used for inhibiting parasitic activity A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myrist... | 04/11/2000 |
| 6037351 | Method of inhibiting hepatitis B virus A method is disclosed for the treatment of hepatitis B virus (HBV) infections which comprises administering to the infected host an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms.... | 03/14/2000 |
| 6025511 | Method of inhibiting parasitic activity A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myrist... | 02/15/2000 |
| 6022948 | Method of cell surface activation and inhibition Disclosed are methods of cell surface activation and inhibition that involve the interaction of an inhibitor of matrix metalloprotease known as TIMP-2, with the enzyme, gelatinase-A (GelA). Critical to the methods of the invention is the discovery of a un... | 02/08/2000 |
| 6001869 | Method of inhibiting parasitic activity A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myrist... | 12/14/1999 |
| 5998642 | Thienyl-containing fatty acid glycosyl phosphatidylinosital analogues used for inhibiting parasitic activity A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myrist... | 12/07/1999 |
| 5981580 | Fatty acid analogs and prodrugs Novel derivatives of fatty acid analogs that have from one to three heteroatoms in the fatty acid moiety which can be oxygen, sulfur or nitrogen, are disclosed in which the carboxy-terminus has been modified to form various amides, esters, ketones, alcoho... | 11/09/1999 |
| 5959145 | Fatty acid analog enzyme substrates Novel oxy- and thio-substituted fatty acid analog substrates of myristoylating enzymes are provided which contain an oxygen or sulfur in place of a methylene group in a carbon position from 4 to 13 in the fatty acid chain of a C13 -C14 | 09/28/1999 |
| 5952377 | Fatty acid analogs and prodrugs Novel derivatives of fatty acid analogs that have from one to three heteroatoms in the fatty acid moiety which can be oxygen, sulfur or nitrogen, are disclosed in which the carboxy-terminus has been modified to form various amides, esters, ketones, alcoho... | 09/14/1999 |
| 5932693 | Antithrombotic peptides Novel short peptides are disclosed which are selected from the group consisting of TAVTQTYGGNSNGEP and fragments thereof containing the minimal sequence TAVTQTY. These peptides are antithrombotic agents and mediate divalent cation-independent adhesion of ... | 08/03/1999 |
| 5929110 | Fatty acid analogs and prodrugs Novel derivatives of fatty acid analogs that have from one to three heteroatoms in the fatty acid moiety which can be oxygen, sulfur or nitrogen, are disclosed in which the carboxy-terminus has been modified to form various amides, esters, ketones, alcoho... | 07/27/1999 |
